[Myocardial infarction remodeling in rats with dinitrosyl iron complex with glutathione].
Effects of dinitrosyl iron complex with reduced glutathione (DNIC-GS) on hemodynamics, metabolic state of the heart and myocardial infarction size were studied in vivo in rats subjected to 40-min occlusion of the anterior descending coronary artery (ADCA) and subsequent 60-min reperfusion. Intravenous bolus injection of DNIC-GS (3.10 or 0.78 micromol/kg body wt) was performed before ADCA occlusion or at the first minute of the reperfusion; the same volume of saline was infused in the control group. Nitroglycerine and nicorandil were used as reference preparations. DNIC-GS administration significantly reduced the mean arterial pressure, thus indicating vasodilative effect of NO releasing. Administration of both doses of DNIC-GS (before ADCA occlusion or at the first minute of the reperfusion) significantly limited the infarction size as compared with that in the control. Preischemic administration of 3.10 micromol DNIC-GS/kg body wt. substantially reduced activities of lactate dehydrogenase and MB-fraction of creatine kinase in blood plasma at the end of the reperfusion compared with these indices in the control. This effect was accompanied with essential improvement of energy state of the area at risk (AR) and with a lack of DNIC-GS influence on metabolism of non-ischemic area of the heart. The obtained results demonstrate that infarction remodelling after intravenous DNIC-GS administration is related to augmented preservation of aerobic metabolism and membrane integrity in post-ischemic cardiomyocytes of the AR.
Pisarenko
O I
OI
Serebriakova
L I
LI
Tskitishvili
O V
OV
Studneva
I M
IM
Vanin
A F
AF
D000818:Animals; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004734:Energy Metabolism / Q000187:drug effects; D005296:Ferrous Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D005978:Glutathione / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006439:Hemodynamics / Q000187:drug effects; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D009206:Myocardium / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
D002316:Cardiotonic Agents; D005296:Ferrous Compounds; C404202:dinitrosylbis(glutathione)iron(II); D009569:Nitric Oxide; D005978:Glutathione